Medical Device News Magazine

AppliedVR Raises $36 Million Series B

To Scale Comprehensive Virtual Reality Platform For Healthcare

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Whether used in clinical settings or by patients on themselves at home, AppliedVR is building an unparalleled body of evidence that demonstrates its immersive therapeutics are effective and usable for patients, scalable for providers and viable for payer reimbursement.

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced $36 million in series B funding, bringing its total funding to $71 million. The round, which included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures, set up AppliedVR for rapid growth as it prepares for its decision from the FDA on its first de novo submission.

Virtual reality provides an immersive experience that has been proven to improve the lives of people experiencing pain. The AppliedVR platform comprehensively addresses multiple pain indicators, leading to people reporting reductions in pain and associated interference of daily life both immediately and for several months after treatment is completed. People suffering from pain follow a science-backed, clinically validated curriculum of immersive VR programming to reduce their pain and help them learn skills for managing pain in the real world.

“For too long, we’ve relied on the notion that people need to take pills or rely on surgery to feel better and lead a better quality of life. At AppliedVR, we’re building an unparalleled body of evidence for providers and payers to demonstrate that immersive therapeutics can fill the massive unmet need for patients who are frustrated by current treatment paradigms. And, we are starting with chronic pain, one of the most complex, costly conditions,” said Matthew Stoudt, co-founder and CEO of AppliedVR. “Our goal is to make immersive therapeutics accessible to everyone, and this funding will help further expand our body of evidence, infrastructure and distribution platform, enabling patients and providers to take advantage of this next-generation therapeutic — while also bringing down costs for payers.”

AppliedVR’s flagship product for chronic pain recently became the first virtual reality (VR) prescription therapeutic to receive FDA Breakthrough Device Designation for treatment-resistant fibromyalgia and chronic intractable lower back pain.

“Virtual reality is now a smart, practical and effective therapy for healthcare because of innovations from companies like AppliedVR. As the pandemic demonstrated, the U.S. healthcare system desperately needs more care access through scalable solutions that are available in people’s homes, and potent therapeutics delivered with VR are a perfect solution,” said Zack Lynch, co-founder and Managing Director of JAZZ Venture Partners. “As the market leader in developing virtual reality-based prescription digital therapies, we are delighted to be backing such an exceptional team at AppliedVR.”

Whether used in clinical settings or by patients on themselves at home, AppliedVR is building an unparalleled body of evidence that demonstrates its immersive therapeutics are effective and usable for patients, scalable for providers and viable for payer reimbursement. In February, AppliedVR released results from its pivotal eight-week randomized clinical trial that found the EaseVRx device produced “clinically meaningful” improvement in multiple pain outcomes and had high participant satisfaction and engagement.

The company also just announced results from a peer-reviewed, collaborative research project with S.O.L.V.E. Health Tech, a health equity incubation partner, embedded within the University of California, San Francisco. The research, published in the Journal for Medical of Internet Research (JMIR), studied how VR could be used for pain management in safety-net settings for vulnerable populations like Medicaid patients.

Pain, especially chronic pain, is one of the most complex and expensive health problems to address. Affecting approximately one-third of all Americans1, chronic pain is estimated2 to cost as high as $635 billion each year, making it more expensive than cancer, heart disease and diabetes combined. Additionally, exacerbated by Covid-19, the chronic pain epidemic continues to fuel America’s opioid crisis, which has decimated communities and compounded the healthcare cost problem. AppliedVR is currently collaborating with Geisinger and Cleveland Clinic to advance separate NIDA-funding clinical trials that test VR as an opioid-sparing tool for acute and chronic pain.

AppliedVR is already trusted by more than 200 of the world’s leading health systems and the technology has been used by more than 60,000 patients to date in pain management and wellness programs. After today’s investment, the company will prepare for EaseVRx’s full market launch after FDA approval, finish additional payer pilots, build out its product pipeline, conduct more clinical research, and continue building its VR pharmacy platform.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.